2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
70
TL;DR: In 2018, the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions as discussed by the authors .
read more
Abstract: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide.
25 Mar 2024
TL;DR: Changing etiology and epidemiology of hepatocellular carcinoma: HCC is primarily caused by HBV infection, but the incidence of HCC related to NASH and NAFLD has increased worldwide.
42
Transarterial Chemoembolization for Hepatocellular Carcinoma: 2023 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association
Yuri Cho,Jin Woo Choi,Hoon Kwon,Kun Yung Kim,Byung Chan Lee,Hee Ho Chu,Dong Hyeon Lee,Gyoung Min Kim,Jung Suk Oh,Dongho Hyun,In Joon Lee,Hyunchul Rhim +11 more
TL;DR: In this article , a group of 12 experts in the fields of interventional radiology and hepatology, convened by the Research Committee of the Korean Liver Cancer Association (KLCA), has developed expert consensus-based practical recommendations in TACE.
27
Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and MR imaging.
TL;DR: In this paper , the authors evaluated the prognostic value of microvascular invasion (MVI) classification and analyzed the radiologic features predictive of MVI in hepatocellular carcinoma (HCC) patients.
Radiologic features of hepatocellular carcinoma related to prognosis
Shin Hye Hwang,Hyungjin Rhee +1 more
TL;DR: Examination of imaging findings related to the prognosis of HCC as well as their associated clinicopathological characteristics is reviewed to decide the treatment strategy for HCC.
11
Multidisciplinary approach for hepatocellular carcinoma patients: current evidence and future perspectives
Joo Hyun Oh,Dong Hyun Sinn +1 more
TL;DR: Multidisciplinary approach for HCC management is promising, but lacks robust evidence and requires increased resources.
References
Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma
TL;DR: In this paper, the authors investigated safety and clinical outcome of PD-1/PD-L1 inhibitors combined with palliative radiotherapy and targeted angiogenesis therapy in hepatocellular carcinoma (HCC) stage C.
Systematic hepatectomy for small hepatocellular carcinoma in Korea.
TL;DR: Although systematic hepatectomy seems to be superior to non-anatomical hepateCTomy from the oncological and anatomical aspects, this superiority is not reflected by the recurrence patterns or the survival and recurrence rates of the two procedures.
35
Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma
Won Mook Choi,Jonggi Choi,Danbi Lee,Ju Hyun Shim,Young-Suk Lim,Han Chu Lee,Young-Hwa Chung,Young-Sang Lee,Sook Ryun Park,Min-Hee Ryu,Baek-Yeol Ryoo,So Jung Lee,Kang Mo Kim +12 more
- 01 Jul 2020
TL;DR: Survival outcomes in patients treated with regorafenib and nivolumab after sorafenIB failure did not differ significantly, however, nivlumab may be more effective than regorAFenib in nonprogressors.
35
A Prospective Phase 2 Multicenter Study for the Efficacy of Radiation Therapy Following Incomplete Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma
Chihwan Choi,Woong Sub Koom,Tae Hyun Kim,Sang Min Yoon,Jinhee Kim,Hyung Sik Lee,Taek Keun Nam,Jinsil Seong +7 more
TL;DR: Early 3D-CRT following incomplete TACE is a safe and practical treatment option for patients with unresectable HCC and is a significant independent prognostic factor for PFS.
35
Outcomes of patients with hepatocellular carcinoma are determined in multidisciplinary team meetings.
Bérénice Charriere,Fabrice Muscari,Charlotte Maulat,Barbara Bournet,Delphine Bonnet,Christophe Bureau,Philippe Otal,Jean-Marie Peron,Bertrand Suc +8 more
TL;DR: To analyze overall survival (OS) rates for the three curative treatments of hepatocellular carcinoma (HCC) on an intention‐to‐treat (ITT) basis, an intention-to-treat basis is considered.
35
Related Papers (5)
T. Hasegawa,Nobuyuki Takemura,Tatsuya Yamashita,Takeyuki Watadani,Masaki Kaibori,Shoji Kubo,M Shimada,Hiroaki Nagano,Etsuro Hatano,Hiroshi Aikata,Hiroko Iijima,Kazuomi Ueshima,Kazuyoshi Ohkawa,Takuya Genda,Kaoru Tsuchiya,Takuji Torimura,Masafumi Ikeda,Junji Furuse,Masaaki Akahane,Satoshi Kobayashi,Hideyuki Sakurai,Atsuya Takeda,Takamichi Murakami,Utaroh Motosugi,Yutaka Matsuyama,Masatoshi Kudo,Ryosuke Tateishi +26 more